|
Prous Institute is at BioAtlanta 09 from 18 to 21 May to present its technology and build partnerships and new collaborations with industry, public health organizations and academia.
The Institute’s business model is based on powerful computational programs and experimental studies (using pharmacogenetics, in vitro and in vivo models).
The technology covers all the major areas involved in the drug discovery and development process. Thus a series of computational models allows the Institute to predict the mechanisms of action, therapeutic use, pharmacokinetics and toxicological profiles of new molecular entities (NMEs). Multimillionaire libraries of small molecular entities are generated by applying computational programs and screening with in silico models.
JR Prous, PhD, President and C.E.O. of Prous Institute, commented “Our mission is to become the leading explorer of the unlimited chemical space for biological activity, turning in silico data into new drugs. This will make R&D spending more efficient”.
The cutting edge technology allows the Institute to simultaneously run a series of research projects covering 23 targets for therapeutic intervention in cancer, neurodegenerative diseases (Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease), diabetes, COPD and psychological stress. Drug pipelines created in silico are synthesized and evaluated in vitro and in vivo using in-house or out-sourced facilities.
About Prous Institute for Biomedical Research
Prous Institute is a research-driven organization committed to discovering and developing innovative therapies by synchronizing powerful computational tools and basic research. The Institute is looking to establish offices in Boston, Tokyo and Shanghai and expects to collaborate with regulatory agencies, academia and industry.
|